Marinomed Biotech files for court restructuring: a signal of the financing winter in the European biotech industry

Event Overview

In May 2025, Austrian biotechnology company Marinomed Biotech AG (hereinafter "Marinomed") announced that it had applied to the court to initiate restructuring proceedings, without self-administration. This means that the company's management will temporarily relinquish control, with the court-appointed administrator leading debt restructuring or asset disposal. Marinomed is a clinical-stage biotech company focused on developing drugs for respiratory and inflammatory diseases, with core assets including allergic rhinitis sprays and other products.

This news did not cause significant volatility in the capital markets, yet it reflects the deep structural adjustments currently underway in the European biotechnology industry.

Macro Background: The "Double Squeeze" of Interest Rate Cycles and Biotech Financing

Since 2022, the Federal Reserve and the European Central Bank have successively launched the most aggressive rate hiking cycles in decades, pushing benchmark interest rates above 5%. For small biotech companies that rely on long-term capital investment and lack stable cash flow, the high-interest-rate environment has delivered a triple blow:

1. Soaring financing costs: The expected rate of return for venture capital and private equity on early-stage biotech projects has risen sharply, leading to valuation declines and a contraction in financing rounds. According to PitchBook data, total European biotech venture capital investment in 2024 was approximately 40% lower than the 2021 peak. 2. Closed secondary markets: The IPO window has nearly shut, listed companies face difficulties in refinancing, and stock prices remain persistently low. Marinomed's share price has fallen by more than 90% since its 2021 high, with its market capitalization shrinking to just a few million euros. 3. Debt rollover risk: Debt accumulated during the low-interest-rate period now faces refinancing pressure. Banks and bond markets have tightened credit to non-profitable pharmaceutical companies, forcing firms to seek judicial protection.

Marinomed's case is not an isolated incident. Since 2024, German biotech company CureVac, French Enterome, and others have undergone large-scale restructuring or asset sales. The European biotech industry is experiencing a "liquidation" phase—removing projects that survived the era of easy money but lack core competitiveness.

Restructuring of Global Capital Flows: A Paradigm Shift from "Growth" to "Profitability"

• Marinomed's restructuring application is essentially a micro-level manifestation of the shift in global capital allocation logic from "favoring growth" to "emphasizing profitability." During the zero-interest-rate era of 2020-2021, a flood of capital poured into high-risk, high-return biotech fields, creating bubble-like valuations. Now, with real interest rates turning positive, investors place greater value on short-term cash flow and clear pathways, significantly reducing their tolerance for preclinical or early-stage clinical projects.This trend manifests differently across the three major economies of China, the United States, and Europe:
• The U.S. biotechnology industry, supported by deep capital markets and mergers and acquisitions by large pharmaceutical companies, still maintains a certain resilience, but small companies also face financing difficulties.
• European biotechnology relies on government subsidies and limited venture capital, with a fragmented industrial chain and a lack of local large pharmaceutical companies as M&A "exit portals," making the adjustment pressure most significant.
• Chinese biotechnology, due to geopolitical and domestic regulatory changes, is experiencing the growing pains of transitioning from "introduction and imitation" to "independent innovation."

Regional economic divergence and fiscal constraints